arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

BIOTRICITY INC.

BTCY
Price unavailable
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
54 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
41
Health
Weak
Bearish
auto_awesome

Analytical Summary

BIOTRICITY INC. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 10.4%
Op. Margin 3.7%
ROIC -0.4%
FCF / Share $0.02
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.28M
↑ +10.4%
Net Income Profit after all expenses
$-959.47K
↓ -42.8%
Operating Margin Operating profit as % of sales
3.7%
↓ -77.4% 67th
FCF / Share Free cash flow per share
$0.02
↑ +181.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
29
Returns
54
Financial Health
45
Cash Quality
30

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 54 quarters